Literature DB >> 7911718

Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart.

M C Michel1, G Hanft, G Gross.   

Abstract

1. In order to characterize the alpha 1-adrenoceptor subtypes mediating positive inotropic effects of adrenaline (in the presence of propranolol) in rat right ventricular strips and the Ca2+ sources used to elicit them, we have used radioligand binding to identify the alpha 1-adrenoceptor subtypes present in rat heart and the alpha 1-adrenoceptor affinity and subtype-selectivity of various pharmacological tools. 2. Amitryptiline, mianserin, trimipramine, oxaprotiline, clonidine, chloroethylclonidine, phenoxybenzamine, BE 2254 and 8-OH-DPAT competed for [3H]-prazosin binding in rat heart, vas deferens, liver, spleen, cerebral cortex and hippocampus but none of them displayed detectable alpha 1-adrenoceptor subtype-selectivity; nitrendipine did not compete for [3H]-prazosin binding in concentrations up to 5 mumol 1(-1). 3. The alpha 1 A-adrenoceptor-selective, 5-methyl-urapidil, (+)-niguldipine, and to a lesser extent (-)-niguldipine competed for [3H]-prazosin binding in rat heart, vas deferens, cerebral cortex and hippocampus with shallow and biphasic curves; analysis of these curves demonstrated that rat heart contains alpha 1A-and alpha 1B-adrenoceptors in a 20:80 ratio. 4. Treatment of rat right ventricular strips with 100 mumol l-1 chloroethylclonidine for 30 min at 30 degrees C followed by 60 min washout reduced the number of alpha 1-adrenoceptors, as assessed by [3H]-prazosin saturation experiments, by 74%. Treatment with 100 micromol l(-1) CdCl2 did not affect number or affinity of cardiac alpha 1-adrenoceptors and combined treatment with chlorethylclonidine and CdCl2 reduced alpha 1-adrenoceptor number by 90%. 5. Treatment of rat right ventricular strips with chloroethylclonidine steepened 5-methyl-urapidil competition curves and increased the relative contribution of alpha 1A-adrenoceptors from 26 to 89%. Treatment with CdCl2 did not affect 5-methyl-urapidil competition curves and combined treatment with chloroethylclonidineand CdCl2 increased the relative contribution of alpha lA-adrenoceptors to 66%.6. We conclude that rat heart contains alpha 1A- and alpha 1B-adrenoceptors in a 20:80% ratio. Treatment withchloroethylclonidine reduces alpha 1B-adrenoceptor number by 96% but has only minor effects on alpha 1A-adrenoceptor density. Treatment with CdCl2 does not affect the number of either alpha 1-adrenoceptor subtype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911718      PMCID: PMC1909949          DOI: 10.1111/j.1476-5381.1994.tb14770.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Alpha and beta-adrenoceptors in hypertension. I. Cardiac and renal alpha 1-, beta 1-, and beta 2-adrenoceptors in rat models of acquired hypertension.

Authors:  M C Michel; R Kanczik; M Khamssi; A Knorr; H Siegl; J J Beckeringh; O E Brodde
Journal:  J Cardiovasc Pharmacol       Date:  1989-03       Impact factor: 3.105

3.  Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists.

Authors:  G Hanft; G Gross
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

4.  Glycogen phosphorylase activation by two different alpha 1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative alpha 1-adrenergic receptor subtype (alpha 1a) that couples with Ca2+ influx.

Authors:  G Tsujimoto; A Tsujimoto; E Suzuki; K Hashimoto
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

5.  (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors.

Authors:  R Boer; A Grassegger; C Schudt; H Glossmann
Journal:  Eur J Pharmacol       Date:  1989-05-11       Impact factor: 4.432

6.  Noradrenaline content and adrenergic receptors in kidney and heart of the prehypertensive and hypertensive Lyon rat strain.

Authors:  A Parini; I Coupry; D Laude; L Diop; M Vincent; J Sassard; J P Dausse
Journal:  Am J Hypertens       Date:  1988-04       Impact factor: 2.689

7.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101.

Authors:  K P Minneman; C Han; P W Abel
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

8.  Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

9.  Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat.

Authors:  G Gross; I Lues
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

10.  Differentiation of alpha 1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain.

Authors:  R D Johnson; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-03       Impact factor: 4.436

View more
  17 in total

1.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

2.  Pharmacokinetic and alpha 1-adrenoceptor antagonistic properties of two cyanine-type inhibitors of extraneuronal monoamine transport.

Authors:  H Russ; B Friedgen; B Königs; C Schumacher; K H Graefe; E Schömig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

3.  Characterization of alpha 1 D-adrenoceptor subtype in rat myocardium, aorta and other tissues.

Authors:  X F Deng; S Chemtob; D R Varma
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 4.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

5.  Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.

Authors:  J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango
Journal:  Brain Res       Date:  2013-02-27       Impact factor: 3.252

6.  Comparison of guinea-pig, bovine and rat alpha 1-adrenoceptor subtypes.

Authors:  R Büscher; C Heeks; K Taguchi; M C Michel
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

7.  The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries.

Authors:  Brian C Jensen; Philip M Swigart; Marie-Eve Laden; Teresa DeMarco; Charles Hoopes; Paul C Simpson
Journal:  J Am Coll Cardiol       Date:  2009-09-22       Impact factor: 24.094

Review 8.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

9.  α₁A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion.

Authors:  Robert S Papay; Ting Shi; Michael T Piascik; Sathyamangla V Naga Prasad; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2013-02-12       Impact factor: 4.436

10.  Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle.

Authors:  M C Michel; G Hanft; G Gross
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.